[{"path":"/articles/vignette-survAH.html","id":"introduction","dir":"Articles","previous_headings":"","what":"1 Introduction","title":"Vignette for survAH package","text":"important objective clinical research investigating safety efficacy new intervention provide quantitative information intervention effect clinical outcomes. quantitative information critical informed treatment decision making balance risks benefits new intervention. studies time--event outcomes clinical endpoints interest, traditional Cox’s hazard ratio (HR) used estimating reporting treatment effect magnitude many decades. However, traditional approach may provided sufficient quantitative information needed informed decision making clinical practice following reasons. First, approach require calculating absolute hazard group order calculate HR, desirable feature statistical point view, makes clinical interpretation difficult. clinical point view, two numbers treatment control groups necessary interpreting -group contrast measure (e.g., difference ratio). Second, proportional hazards assumption correct, interpretation HR obvious affected underlying study-specific censoring time distribution.[1,2] average hazard survival weight (AHSW), can interpreted general censoring-free incidence rate (CFIR), summary measure event time distribution depend underlying study-specific censoring time distribution. approach using AHSW (CFIR) provides two numbers treatment control groups allows us summarize treatment effect magnitude absolute relative terms, enhance clinical interpretation treatment effect time--event outcomes.[3] vignette supplemental documentation survAH package illustrates use functions package compare two groups respect AHSW (CFIR). package made tested R version 4.2.2.","code":""},{"path":"/articles/vignette-survAH.html","id":"installation","dir":"Articles","previous_headings":"","what":"2 Installation","title":"Vignette for survAH package","text":"Open R RStudio applications. , copy paste either following scripts command line. install package CRAN: install development version:","code":"install.packages(\"survAH\") install.packages(\"devtools\") #-- if the devtools package has not been installed devtools::install_github(\"uno1lab/survAH\")"},{"path":"/articles/vignette-survAH.html","id":"sample-reconstructed-data","dir":"Articles","previous_headings":"","what":"2 Sample Reconstructed Data","title":"Vignette for survAH package","text":"Throughout vignette, use sample reconstructed data CheckMate214 study reported Motzer et al. [4] data consists 847 patients previously untreated clear-cell advanced renal-cell carcinoma; 425 nivolumab plus ipilimumab group (treatment) 422 sunitinib group (control). sample reconstructed data CheckMate214 study available survAH package cm214_pfs. load data, copy paste following scripts command line. , time months registration progression-free survival (PFS), status indicator event (1: event, 0: censor), arm treatment assignment indicator (1: Treatment group, 0: Control group). Kaplan-Meier estimates PFS treatment group.  two survival curves showed similar trajectories six months, , difference appeared two groups. -called delayed difference pattern often seen immunotherapy trials. HR based traditional Cox’s method 0.82 (0.95CI: 0.68 0.99, p-value=0.037). Since validity proportional hazards assumption clear study, clear interpretation reported HR. Even proportional hazards assumption seemed reasonable, lack group-specific absolute value regarding hazard makes clinical interpretation treatment effect difficult. example, baseline absolute hazard low, reported HR (0.82) may indicate clinically ignorable treatment effect magnitude. high, even HR closer 1 (e.g., 0.98) may indicate clinically significant treatment effect magnitude.","code":"library(survAH)  nrow(cm214_pfs) #> [1] 847  head(cm214_pfs) #>    time status arm #> 1 0.451      1   1 #> 2 0.451      1   1 #> 3 0.451      1   1 #> 4 0.451      1   1 #> 5 0.451      1   1 #> 6 0.710      1   1"},{"path":"/articles/vignette-survAH.html","id":"average-hazard-with-survival-weight-ahsw","dir":"Articles","previous_headings":"","what":"3 Average Hazard with Survival Weight (AHSW)","title":"Vignette for survAH package","text":"given \\(\\tau,\\) general form average hazard (AH) denoted \\[ \\eta(t) = \\frac{\\int_0^\\tau h(u)w(u)du}{\\int_0^\\tau w(u)du},\\] \\(h(t)\\) \\(w(t)\\) hazard function event time \\(T,\\) non-negative weight function, respectively. Let \\(S(t)\\) survival function \\(T.\\) use \\(S(t)\\) weight, gives AHSW \\[ \\eta(t) = \\frac{\\int_0^\\tau h(u)S(u)du}{\\int_0^\\tau S(u)du}.\\] detailed motivation using \\(S(t)\\) \\(w(t)\\) discussed Uno Horiguchi [3]. AHSW clear interpretation average person-time incidence rate given time window \\([0,\\tau].\\) can also called general censoring-free incidence rate (CFIR) contrast conventional person-time incidence rate potentially depends underlying study-specific censoring time distribution. now , simply call AHSW (CFIR) average hazard (AH). AH denoted ratio cumulative incidence probability restricted mean survival time \\(\\tau < \\infty\\): \\[ \\eta(\\tau) = \\frac{1-S(\\tau)}{\\int_0^\\tau S(t)dt}.\\] Let \\(\\hat{S}(t)\\) denote Kaplan-Meier estimator \\(S(t).\\) natural estimator \\(\\eta(\\tau)\\) given \\[ \\hat{\\eta}(\\tau) = \\frac{1-\\hat{S}(\\tau)}{\\int_0^\\tau \\hat{S}(t)dt}.\\] large sample properties standard error formula \\(\\hat{\\eta}(\\tau)\\) given Uno Horiguchi [3].","code":""},{"path":"/articles/vignette-survAH.html","id":"two-sample-comparison-using-ah-and-its-implementation","dir":"Articles","previous_headings":"","what":"4 Two-sample comparison using AH and its implementation","title":"Vignette for survAH package","text":"Let \\(\\eta_{1}(\\tau)\\) \\(\\eta_{0}(\\tau)\\) denote AH treatment group 1 0, respectively. Now, compare two survival curves, using AH. Specifically, consider following two measures capture -group contrast: Difference AH (DAH) \\[ \\eta_{1}(\\tau) - \\eta_{0}(\\tau) \\] Ratio AH (RAH) \\[ \\eta_{1}(\\tau) / \\eta_{0}(\\tau) \\] estimated simply replacing \\(\\eta_{1}(\\tau)\\) \\(\\eta_{0}(\\tau)\\) empirical counterparts (.e., \\(\\hat{\\eta_{1}}(\\tau)\\) \\(\\hat{\\eta_{0}}(\\tau)\\), respectively). inference ratio type metrics, use delta method calculate standard error. Specifically, consider \\(\\log \\{ \\hat{\\eta_{1}}(\\tau)\\}\\) \\(\\log \\{ \\hat{\\eta_{0}}(\\tau)\\}\\) calculate standard error log-AH. calculate confidence interval log-ratio AH, transform back original ratio scale; detailed formula given [4]. procedures show use function, ah2, implement analyses. first argument (time) time--event vector variable. second argument (status) also vector variable length time, elements takes either 1 (event) 0 (event). third argument (arm) vector variable indicate assigned treatment subject; elements vector take either 1 (active treatment arm) 0 (control arm). fourth argument (tau) scalar value specify truncation time point \\({\\tau}\\) AH calculation. \\(\\tau\\) specified ah2, (.e., code looks like ) default \\(\\tau\\) (.e., maximum time point size risk set groups remains least 10) used calculate AH. best confirm size risk set large enough specified \\(\\tau\\) group make sure Kaplan-Meier estimates stable. ah2 function returns AH group results -group contrast measures listed . Note chose 21 months \\(\\tau\\) example. estimated AHs 0.049 (0.95CI: 0.042 0.057) 0.066 (0.95CI: 0.057 0.076) treatment group control group, respectively. ratio difference AH 0.747 (0.95CI: 0.608 0.917, p-value=0.005) -0.017 (0.95CI: -0.029 -0.005, p-value=0.006), respectively.","code":"time   = cm214_pfs$time status = cm214_pfs$status arm    = cm214_pfs$arm ah2(time, status, arm, tau=21) ah2(time, status, arm) obj = ah2(time, status, arm, tau=21) print(obj, digits=3) #>  #> The truncation time: tau = 21 was specified. #>  #> Number of observations:  #>      Total N Event by tau Censor by tau At risk at tau #> arm0     422          225           163             34 #> arm1     425          219           160             46 #>  #>  #> Average Hazard (AH) by arm:  #>            Est. Lower 0.95 Upper 0.95 #> AH (arm0) 0.066      0.057      0.076 #> AH (arm1) 0.049      0.042      0.057 #>  #>  #> Between-group contrast:  #>                                Est. Lower 0.95 Upper 0.95 P-value #> Ratio of AH (arm1/arm0)       0.747      0.608      0.917   0.005 #> Difference of AH (arm1-arm0) -0.017     -0.029     -0.005   0.006"},{"path":"/articles/vignette-survAH.html","id":"conclusions","dir":"Articles","previous_headings":"","what":"5 Conclusions","title":"Vignette for survAH package","text":"illustrated, presented approach using AHSW provides robust reliable quantitative information treatment effect time--event outcomes traditional Cox’s hazard ratio approach. hope AHSW-based approach, along survAH package, helpful clinical researchers providing interpretable quantitative information treatment effect magnitude, ultimately foster better informed decision making.","code":""},{"path":"/articles/vignette-survAH.html","id":"references","dir":"Articles","previous_headings":"","what":"References","title":"Vignette for survAH package","text":"[1] Uno H, Claggett B, Tian L, et al. (2014). Moving beyond hazard ratio quantifying -group difference survival analysis. Journal clinical oncology : official journal American Society Clinical Oncology 32, 2380-2385. https://doi.org/10.1200/JCO.2014.55.2208 [2] Horiguchi M, Hassett MJ, Uno H (2019). accrual pattern follow-duration affect hazard ratio estimate proportional hazards assumption violated? Oncologist 24(7), 867-871. https://doi.org/10.1634/theoncologist.2018-0141 [3] Uno H Horiguchi M (2023). Ratio difference average hazard survival weight: new measures quantify survival benefit new therapy. Statistics Medicine Online first, 1-17. https://doi.org/10.1002/sim.9651 [4] Motzer RJ, Tannir NM, McDermott DF, et al. (2018). Nivolumab plus ipilimumab versus sunitinib advanced renal-cell carcinoma. New England Journal Medicine 378(14), 1277–1290. https://doi.org/10.1056/NEJMoa1712126","code":""},{"path":"/articles/vignette.html","id":"introduction","dir":"Articles","previous_headings":"","what":"1 Introduction","title":"Vignette for survAH package","text":"important objective clinical research investigating safety efficacy new intervention provide quantitative information intervention effect clinical outcomes. quantitative information critical informed treatment decision making risk benefit new intervention balanced. studies time--event outcomes clinical endpoints interest, traditional Cox’s hazard ratio taking role estimating reporting treatment effect magnitude many decades. However, traditional approach may well achieved objective clinicial point view. First, approach require calculating absolute hazard group calculate havard ratio, desirable feature statistical point view makes clinical interpretation difficult. clinical point view, two numbers treatment control groups necessary interpreting -group contrast measure (e.g., difference ratio) well. Second, proportional hazards assumption correct, interpretation HR obvious affected underlying study-specific censoring time distribution.[1,2] average hazard survival weight (AHSW), can interpreted general censoring-free incidence rate (CFIR), summary measure event time distribution depend study-specific censoring time distribution. approach using AHSW (CFIR) provides two numbers treatment control groups allows us summarize treatment effect magnitude absoluate relative terms, enhance clinical interpretation treatment effect time--event outcomes.[3] vignette supplemental documentation survAH package illustrates use functions package compare two groups respect AHSW (CFIR). package made tested R version 4.2.0.","code":""},{"path":"/articles/vignette.html","id":"installation","dir":"Articles","previous_headings":"","what":"2 Installation","title":"Vignette for survAH package","text":"install package CRAN: install development version:","code":"install.packages(\"survAH\") install.packages(\"devtools\") #-- if the devtools package has not been installed devtools::install_github(\"uno1lab/survAH\")"},{"path":"/articles/vignette.html","id":"sample-reconstructed-data","dir":"Articles","previous_headings":"","what":"2 Sample Reconstructed Data","title":"Vignette for survAH package","text":"Throughout vignette, use sample reconstructed data CheckMate214 study reported Motzer et al. [4] data consists 847 patients previously untreated clear-cell advanced renal-cell carcinoma; 425 nivolumab plus ipilimumab group (treatment) 422 sunitinib group (control). sample reconstructed data CheckMate214 study available survAH package cm214_pfs. , time months registration progression-free survival (PFS), status indicator event (1: event, 0: censor), arm treatment assignment indicator (1: Treatment group, 0: Control group). Kaplan-Meier (KM) estimates PFS treatment group.  two survival curves showed similar trajectories six months, appeared difference two groups . -called delayed difference pattern often seen immunotherapy trials. hazard ratio based traditional Cox’s method 0.82 (0.95CI: 0.68 0.99, p-value=0.037). Since validity proportional hazards assumption clear study, clear interpretation reported hazard ratio. Even proportional hazards assumption seemed reasonable, lack group-specific absolute value regarding hazard makes clinical interpretation treatment effect difficult. example, baseline absolute hazard low, reported HR (0.82) may indicate clinically ignoble treatment effect magnitude. high, even HR closer 1 (e.g., 0.98) may indicate clinically significant treatment effect magnitude.","code":"library(survAH)  nrow(cm214_pfs) #> [1] 847  head(cm214_pfs) #>    time status arm #> 1 0.451      1   1 #> 2 0.451      1   1 #> 3 0.451      1   1 #> 4 0.451      1   1 #> 5 0.451      1   1 #> 6 0.710      1   1"},{"path":"/articles/vignette.html","id":"average-hazard-with-survival-weight-ahsw","dir":"Articles","previous_headings":"","what":"3 Average Hazard with Survival Weight (AHSW)","title":"Vignette for survAH package","text":"given \\(\\tau,\\) general form average hazard denoted \\[ \\eta(t) = \\frac{\\int_0^\\tau h(u)w(u)du}{\\int_0^\\tau w(u)du},\\] \\(h(t)\\) \\(w(t)\\) hazard function event time \\(T,\\) non-negative weight function, respectively. Let \\(S(t)\\) survival function \\(T.\\) consider using \\(S(t)\\) weight, gives AHSW \\[ \\eta(t) = \\frac{\\int_0^\\tau h(u)S(u)du}{\\int_0^\\tau S(u)du}.\\] detailed motivation using \\(S(t)\\) \\(w(t)\\) discussed Uno Horiguchi [3]. AHSW clear interpretation average person-time incidence rate given time window \\([0,\\tau].\\) can also called general censoring-free incidence rate (CFIR) contrast conventional person-time incidence rate potentially depends underlying study-specific censoring time distribution. now , simply call AHSW (CFIR) average hazard (AH). AH denoted ratio cumulative incidence probability restricted mean survival time \\(\\tau < \\infty\\): \\[ \\eta(\\tau) = \\frac{1-S(\\tau)}{\\int_0^\\tau S(t)dt}.\\] Let \\(\\hat{S}(t)\\) denote Kaplan-Meier estimator \\(S(t).\\) natural estimator \\(\\eta(\\tau)\\) given \\[ \\hat{\\eta}(\\tau) = \\frac{1-\\hat{S}(\\tau)}{\\int_0^\\tau \\hat{S}(t)dt}.\\] large sample properties standard error formula \\(\\hat{\\eta}(\\tau)\\) given Uno Horiguchi [3].","code":""},{"path":"/articles/vignette.html","id":"two-sample-comparison-using-ah-and-its-implementation","dir":"Articles","previous_headings":"","what":"4 Two-sample comparison using AH and its implementation","title":"Vignette for survAH package","text":"Let \\(\\eta_{\\tau}(1)\\) \\(\\eta_{\\tau}(0)\\) denote AH treatment group 1 0, respectively. Now, compare two survival curves, using AH. Specifically, consider following two measures -group contrast. Difference AH (DAH) \\[ \\eta_{1}(\\tau) - \\eta_{0}(\\tau) \\] Ratio AH (RAH) \\[ \\eta_{1}(\\tau) / \\eta_{0}(\\tau) \\] estimated simply replacing \\(\\eta_{1}(\\tau)\\) \\(\\eta_{0}(\\tau)\\) empirical counterparts (.e.,\\(\\hat{\\eta_{1}}(\\tau)\\) \\(\\hat{\\eta_{0}}(\\tau)\\), respectively). inference ratio type metrics, use delta method calculate standard error. Specifically, consider \\(\\log \\{ \\hat{\\eta_{1}}(\\tau)\\}\\) \\(\\log \\{ \\hat{\\eta_{0}}(\\tau)\\}\\) calculate standard error log-AH. calculate confidence interval log-ratio AH, transform back original ratio scale; detailed formula given [4]. shows use function, ah2, implement analyses. first argument (time) time--event vector variable. second argument (status) also vector variable length time, elements takes either 1 (event) 0 (event). third argument (arm) vector variable indicate assigned treatment subject; elements vector take either 1 (active treatment arm) 0 (control arm). fourth argument (tau) scalar value specify truncation time point \\({\\bf \\tau}\\) AH calculation. Note \\(\\tau\\) needs smaller minimum time point largest observed time two groups (default \\(\\tau\\)). \\(\\tau\\) specified ah2, (.e., code looks like) default \\(\\tau\\) (.e.,minimum time point largest observed time two groups) used calculate AH. always encouraged confirm size risk set large enough specified \\(\\tau\\) group make sure stability KM estimates. ah2 function returns AH group results -group contrast measures listed . Note chose 21 months \\(\\tau\\) example. estimated AH 0.049 (0.95CI: 0.042 0.057) 0.066 (0.95CI: 0.057 0.076) treatment group control group, respectively. ratio difference AH 0.747 (0.95CI: 0.608 0.917, p-value=0.005) -0.017 (0.95CI: -0.029 -0.005, p-value=0.006), respectively.","code":"time   = cm214_pfs$time status = cm214_pfs$status arm    = cm214_pfs$arm ah2(time, status, arm, tau=21) ah2(time, status, arm) obj = ah2(time, status, arm, tau=21) print(obj, digits=3) #>  #> Average Hazard (AH) by arm  #>            Est. Lower 0.95 Upper 0.95 #> AH (arm0) 0.066      0.057      0.076 #> AH (arm1) 0.049      0.042      0.057 #>  #>  #> Between-group contrast  #>                                Est. Lower 0.95 Upper 0.95 P-value #> Ratio of AH (arm1/arm0)       0.747      0.608      0.917   0.005 #> Difference of AH (arm1-arm0) -0.017     -0.029     -0.005   0.006"},{"path":"/articles/vignette.html","id":"conclusions","dir":"Articles","previous_headings":"","what":"5 Conclusions","title":"Vignette for survAH package","text":"illustrated, presented approash using AHSW provides robust reliable quantitative information treatment effect time--event outcomes traditional Cox’s hazard ratio approach. hope AHSW-based approach, along survAH package, helpful clinical researchers provide interpretable information treatment effect magnitude, ultimately foster better informed decision making.","code":""},{"path":"/articles/vignette.html","id":"references","dir":"Articles","previous_headings":"","what":"References","title":"Vignette for survAH package","text":"[1] Uno H, Claggett B, Tian L, et al. (2014). Moving beyond hazard ratio quantifying -group difference survival analysis. Journal clinical oncology : official journal American Society Clinical Oncology 32, 2380-2385. DOI:10.1200/JCO.2014.55.2208 [2] Horiguchi M, Hassett MJ, Uno H (2019). accrual pattern follow-duration affect hazard ratio estimate proportional hazards assumption violated? Oncologist 24(7), 867-871. DOI:10.1634/theoncologist.2018-0141 [3] Uno H Horiguchi M (2023). Ratio difference average hazard survival weight: new measures quantify survival benefit new therapy. Statistics Medicine DOI:10.1002/sim.9651 [4] Motzer RJ, Tannir NM, McDermott DF, et al. (2018). Nivolumab plus ipilimumab versus sunitinib advanced renal-cell carcinoma. New England Journal Medicine 378(14), 1277–1290. DOI:10.1056/NEJMoa1712126.","code":""},{"path":"/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Hajime Uno. Author. Miki Horiguchi. Author, maintainer.","code":""},{"path":"/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Uno H, Horiguchi M (2023). survAH: Survival Data Analysis using Average Hazard. R package version 1.0.0.","code":"@Manual{,   title = {survAH: Survival Data Analysis using Average Hazard},   author = {Hajime Uno and Miki Horiguchi},   year = {2023},   note = {R package version 1.0.0}, }"},{"path":"/index.html","id":"survah-survival-data-analysis-using-average-hazard","dir":"","previous_headings":"","what":"Comparing Average Hazard with Survival Weight","title":"Comparing Average Hazard with Survival Weight","text":"survAH package performs two-sample comparisons based average hazard survival weight (AHSW) general censoring-free incidence rate (CFIR).","code":""},{"path":"/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Comparing Average Hazard with Survival Weight","text":"install package CRAN: install updated version:","code":"install.packages(\"survAH\") devtools::install_github(\"uno1lab/survAH\")"},{"path":"/index.html","id":"usage","dir":"","previous_headings":"","what":"Usage","title":"Comparing Average Hazard with Survival Weight","text":"Please see package vignette.","code":""},{"path":"/index.html","id":"reference","dir":"","previous_headings":"","what":"Reference","title":"Comparing Average Hazard with Survival Weight","text":"Uno H Horiguchi M. Ratio difference average hazard survival weight: new measures quantify survival benefit new therapy. Statistics Medicine. 2023;1-17. https://doi.org/10.1002/sim.9651","code":""},{"path":"/reference/ah2.html","id":null,"dir":"Reference","previous_headings":"","what":"Two-Sample Comparison of Average Hazard — ah2","title":"Two-Sample Comparison of Average Hazard — ah2","text":"ah2 function performs two-sample comparisons using average hazard (AH) summary measure survival time distribution. Two kinds -group contrast metrics, ratio AH (RAH) difference AH (DAH), calculated.","code":""},{"path":"/reference/ah2.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Two-Sample Comparison of Average Hazard — ah2","text":"","code":"ah2(time, status, arm, tau=NULL, conf.int=0.95)"},{"path":"/reference/ah2.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Two-Sample Comparison of Average Hazard — ah2","text":"time follow-time right censored data. status event indicator, 1=event, 0=right censored. arm group indicator comparison. elements vector take either 1 0. Normally, 0=control group, 1=active treatment group. tau scalar value specify time point calculating average hazard. tau=NULL, default value (.e., maximum time point size risk set groups remains least 10) used. conf.int confidence coefficient calculating confidence intervals. default conf.int=0.95.","code":""},{"path":"/reference/ah2.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Two-Sample Comparison of Average Hazard — ah2","text":"object class ah2. note truncation time point used analysis n.obs number observations (total number, number events tau, number censoring tau, size risk set tau) ah estimated average hazard arm rah ratio average hazards (RAH; treatment control) dah difference average hazard (DAH; treatment minus control)","code":""},{"path":"/reference/ah2.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Two-Sample Comparison of Average Hazard — ah2","text":"function provides AH two groups, absolute difference absolute ratio AH (DAH RAH) two groups, corresponding confidence intervals. also calculates p-values two-sided tests based RAH DAH.","code":""},{"path":"/reference/ah2.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Two-Sample Comparison of Average Hazard — ah2","text":"Horiguchi M Uno H. Ratio difference average hazard survival weight: new measures quantify survival benefit new therapy. Statistics Medicine. 2023;1-17. <doi:10.1002/sim.9651>","code":""},{"path":"/reference/ah2.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"Two-Sample Comparison of Average Hazard — ah2","text":"Hajime Uno, Miki Horiguchi","code":""},{"path":"/reference/ah2.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Two-Sample Comparison of Average Hazard — ah2","text":"","code":"#==================================================================== # cm214_pfs: The sample reconstructed data of the CheckMate214 study. # The code below reproduces the results reported by # Uno and Horiguchi (StatMed; 2023) in Table 6. #==================================================================== D      = cm214_pfs time   = D$time status = D$status arm    = D$arm tau    = 21  a = ah2(time=time, status=status, arm=arm, tau=tau, conf.int=0.95) print(a, digits=3) #>  #> The truncation time: tau = 21 was specified. #>  #> Number of observations:  #>      Total N Event by tau Censor by tau At risk at tau #> arm0     422          225           163             34 #> arm1     425          219           160             46 #>  #>  #> Average Hazard (AH) by arm:  #>            Est. Lower 0.95 Upper 0.95 #> AH (arm0) 0.066      0.057      0.076 #> AH (arm1) 0.049      0.042      0.057 #>  #>  #> Between-group contrast:  #>                                Est. Lower 0.95 Upper 0.95 P-value #> Ratio of AH (arm1/arm0)       0.747      0.608      0.917   0.005 #> Difference of AH (arm1-arm0) -0.017     -0.029     -0.005   0.006"},{"path":"/reference/ah2.sample.data.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate a sample data from the pbc data — ah2.sample.data","title":"Generate a sample data from the pbc data — ah2.sample.data","text":"function retrieve 312 randomized patients pbc data survival package.","code":""},{"path":"/reference/ah2.sample.data.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate a sample data from the pbc data — ah2.sample.data","text":"","code":"ah2.sample.data()"},{"path":"/reference/ah2.sample.data.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Generate a sample data from the pbc data — ah2.sample.data","text":"function creates sample dataset illustrate usage function ah2() package. original pbc data survival package consists 418 patients data. function loads pbc data, select 312 patients randomized. status variable edited, 1 indicates death 0 indicates alive.","code":""},{"path":[]},{"path":"/reference/ah2.sample.data.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Generate a sample data from the pbc data — ah2.sample.data","text":"","code":"D=surv2test.sample.data() #> Error in surv2test.sample.data(): could not find function \"surv2test.sample.data\" head(D) #>                                #> 1 function (expr, name)        #> 2 .External(C_doD, expr, name)"},{"path":"/reference/cm214_pfs.html","id":null,"dir":"Reference","previous_headings":"","what":"Sample Reconstructed Data of CheckMate214 Study — cm214_pfs","title":"Sample Reconstructed Data of CheckMate214 Study — cm214_pfs","text":"progression-free survival data reconstructed publication CheckMate214 study.","code":""},{"path":"/reference/cm214_pfs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Sample Reconstructed Data of CheckMate214 Study — cm214_pfs","text":"","code":"data(cm214_pfs)"},{"path":"/reference/cm214_pfs.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Sample Reconstructed Data of CheckMate214 Study — cm214_pfs","text":"dataset containing 3 columns: time time--event variable (time unit month) status event indicator (1=event, 0=censor) arm treatment indicator (1=treatment, 0=control)","code":""},{"path":"/reference/cm214_pfs.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"Sample Reconstructed Data of CheckMate214 Study — cm214_pfs","text":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib advanced renal-cell carcinoma. New England Journal Medicine. 2018;378(14):1277–1290. <doi:10.1056/NEJMoa1712126> Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis survival data: reconstructing data published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. <doi:10.1186/1471-2288-12-9>","code":""},{"path":"/reference/cm214_pfs.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Sample Reconstructed Data of CheckMate214 Study — cm214_pfs","text":"reconstructed patient-level data results reported Motzer et al.(2018) <doi:10.1056/NEJMoa1712126>. data consists 847 patients previously untreated clear-cell advanced renal-cell carcinoma; 425 nivolumab plus ipilimumab group (treatment) 422 sunitinib group (control).","code":""},{"path":"/reference/print.ah2.html","id":null,"dir":"Reference","previous_headings":"","what":"print.ah2 — print.ah2","title":"print.ah2 — print.ah2","text":"S3 method class 'ah2'","code":""},{"path":"/reference/print.ah2.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"print.ah2 — print.ah2","text":"","code":"# S3 method for ah2 print(x, digits=3, ...)"},{"path":"/reference/print.ah2.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"print.ah2 — print.ah2","text":"x Object printed. digits Integer indicating number decimal places. ... arguments ignored function.","code":""},{"path":"/reference/print.ah2.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"print.ah2 — print.ah2","text":"returns summary output class 'ah2'","code":""},{"path":"/reference/survAH-package.html","id":null,"dir":"Reference","previous_headings":"","what":"Survival Data Analysis using Average Hazard — survAH-package","title":"Survival Data Analysis using Average Hazard — survAH-package","text":"survAH package performs two-sample comparisons based average hazard survival weight (AHSW) general censoring-free incidence rate (CFIR) proposed Uno Horiguchi (2023) <doi:10.1002/sim.9651>.","code":""},{"path":"/reference/survAH-package.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Survival Data Analysis using Average Hazard — survAH-package","text":"Uno H Horiguchi M. Ratio difference average hazard survival weight: new measures quantify survival benefit new therapy. Statistics Medicine. 2023;1-17. <doi:10.1002/sim.9651>","code":""},{"path":[]},{"path":"/reference/survAH-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"Survival Data Analysis using Average Hazard — survAH-package","text":"Hajime Uno, Miki Horiguchi","code":""},{"path":"/reference/survAH.sample.data.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate a sample data from the pbc data — survAH.sample.data","title":"Generate a sample data from the pbc data — survAH.sample.data","text":"function retrieve 312 randomized patients pbc data survival package.","code":""},{"path":"/reference/survAH.sample.data.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate a sample data from the pbc data — survAH.sample.data","text":"","code":"survAH.sample.data()"},{"path":"/reference/survAH.sample.data.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Generate a sample data from the pbc data — survAH.sample.data","text":"function creates sample dataset illustrate usage function ah2() package. original pbc data survival package consists 418 patients data. function loads pbc data, select 312 patients randomized. status variable edited, 1 indicates death 0 indicates alive.","code":""},{"path":[]},{"path":"/reference/survAH.sample.data.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Generate a sample data from the pbc data — survAH.sample.data","text":"","code":"D=survAH.sample.data() head(D) #>        time status arm #> 1  1.095140      1   1 #> 2 12.320329      0   1 #> 3  2.770705      1   1 #> 4  5.270363      1   1 #> 5  4.117728      0   0 #> 6  6.852841      1   0"},{"path":"/reference/survAH2-package.html","id":null,"dir":"Reference","previous_headings":"","what":"Comparing Average Hazard With Survival Weight — survAH2-package","title":"Comparing Average Hazard With Survival Weight — survAH2-package","text":"Performs two-sample comparisons using restricted mean survival time (RMST) summary measure survival time distribution. Three kinds -group contrast metrics (.e., difference RMST, ratio RMST ratio restricted mean time lost (RMTL)) computed. package function perform ANCOVA-type covariate adjustment well unadjusted analyses measures.","code":""},{"path":"/reference/survAH2-package.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Comparing Average Hazard With Survival Weight — survAH2-package","text":"Statistics Medicine. 2023. DOI: TBD","code":""},{"path":[]},{"path":"/reference/survAH2-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"Comparing Average Hazard With Survival Weight — survAH2-package","text":"Miki Horiguchi, Hajime Uno","code":""},{"path":"/news/index.html","id":"survah-version-100-2023-01-16","dir":"Changelog","previous_headings":"","what":"survAH version 1.0.0 (2023-01-16)","title":"survAH version 1.0.0 (2023-01-16)","text":"Initial release","code":""}]
